BIO-TECHNE Corp 4

Steven C. Crouse netted additional Bio-Techne Corp common shares through an option-related acquisition of 600 shares and a tax-withholding disposition of 216 shares, while updating and correcting his RSU and option holdings.

On June 2, 2026, Steven C. Crouse, President - Diagnostics & Spatial Biology at Bio-Techne Corp, effected an option-related transaction in which 600 shares of common stock were acquired via the exercise or conversion of derivative equity (coded “M”) and 216 shares of common stock were withheld or sold to cover tax obligations at an average price of $49.77 (coded “F”), resulting in a net increase in directly owned common shares to 6,761. The filing also updates and restates his derivative equity holdings, including multiple tranches of restricted stock units (time-based and performance-based) and stock options with various strike prices and maturities, and corrects a prior mathematical error by increasing his reported beneficial ownership by 40 shares. Overall, this Form 4 reflects routine equity compensation activity, tax withholding, and a clean-up of previously reported holdings rather than an open-market purchase or discretionary sale.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

sec

Accession

0000914190-26-000096

Alert Tier

5